학술논문
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation : I-MOVECOVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
Document Type
Author
Rose, Angela M.C.; Nicolay, Nathalie; Martín, Virginia Sandonis; Mazagatos, Clara; Petrović, Goranka; Baruch, Joaquin; Denayer, Sarah; Seyler, Lucie; Domegan, Lisa; Launay, Odile; Machado, Ausenda; Burgui, Cristina; Vaikutyte, Roberta; Niessen, F. Annabel; Loghin, Isabela I.; Husa, Petr; Aouali, Nassera; Panagiotakopoulos, George; Tolksdorf, Kristin; Horváth, Judit Krisztina; Howard, Jennifer; Pozo, Francisco; Gallardo, Virtudes; Nonković, Diana; Džiugytė, Aušra; Bossuyt, Nathalie; Demuyser, Thomas; Duffy, Róisín; Nguyen, Liem Binh Luong; Kislaya, Irina; Martínez-Baz, Iván; Gefenaite, Giedre; Knol, Mirjam J.; Popescu, Corneliu; Součková, Lenka; Simon, Marc; Michelaki, Stella; Reiche, Janine; Ferenczi, Annamária; Delgado-Sanz, Concepción; Makarić, Zvjezdana Lovrić; Cauchi, John Paul; Barbezange, Cyril; Van Nedervelde, Els; O’Donnell, Joan; Durier, Christine; Guiomar, Raquel; Castilla, Jesús; Jonikaite, Indrė; Bruijning-Verhagen, Patricia C.J.L.
Source
Eurosurveillance EpiHealth: Epidemiology for Health. 28(47)
Subject
Language
English
ISSN
1025-496X
Abstract
Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received≥14 days before symptom onset (stratifying first booster into received<150 and≥150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29–54) for complete PSV (with last dose received≥150 days before onset), while it was 59% (95% CI: 51–66) after addition of one booster dose. The VE was 85% (95% CI: 78–89), 70% (95% CI: 61–77) and 36% (95% CI: 17–51) for those with onset 14–59 days, 60–119 days and 120–179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset<120 days after first booster dose.